High levels of Ki-67 are significantly associated with worse OS and DFS as discussed elsewhere [6, 7], and it represents a crucial factor for adjuvant treatment selection in clinical practice, for example, in the choice of addition of chemotherapy to hormone therapy in estrogen-receptor (ER) and progesterone-receptor (PgR) expressing breast cancer. Here, ESR1 is linked to breast carcinoma.